01332 透雲生物
按盘价 
0.170 -0.005 (-2.857%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -35.978% | -20.713% | -7.307% | -18.164% | -20.777% |
| 股东资金回报率 (%) | -204.430% | -53.978% | -15.230% | -32.796% | -31.627% |
| 资本运用回报率 (%) | -118.670% | -41.462% | -14.732% | -29.900% | -36.148% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | 28.276% | 39.472% | 39.450% | 44.164% | 34.177% |
| 未计利息、税项、折旧及摊销前利润率 (%) | -115.490% | -44.688% | -28.585% | -39.932% | -62.834% |
| 税前边际利润率 (%) | -137.647% | -61.603% | -42.198% | -78.601% | -59.063% |
| 纯利率 (%) | -135.806% | -61.257% | -25.032% | -77.135% | -60.765% |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 0.427 X | 0.785 X | 0.506 X | 1.150 X | 1.100 X |
| 速动比率 (X) | 0.387 X | 0.699 X | 0.445 X | 1.067 X | 1.011 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 96.530% | 68.062% | 52.471% | 42.757% | 38.564% |
| 总债项 / 总资产比率 (%) | 63.376% | 44.499% | 31.109% | 22.905% | 29.434% |
| 净债项 / 总资产比率 (%) | 57.697% | 30.068% | 25.234% | 8.250% | 24.869% |
| 总债项 / 股东资金比率 (%) | N/A | 149.650% | 67.837% | 45.615% | 48.207% |
| 长期债项 / 股东资金比率 (%) | N/A | 73.569% | 1.728% | 1.658% | 1.873% |
| 净债项 / 股东资金比率 (%) | N/A | 101.120% | 55.027% | 16.429% | 40.732% |
| 净现金 / (债项) ($) | (3.50亿) | (2.67亿) | (2.59亿) | (8.02千万) | (2.20亿) |
| 每股净现金 / (债项) ($) | (0.125) | (0.095) | (0.092) | (0.029) | (0.090) |
| 总债项 / 资本运用比率 (%) | 169.843% | 82.691% | 64.378% | 39.440% | 47.034% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 65.352日 | 63.765日 | 68.787日 | 94.575日 | 54.756日 |
| 应收贸易帐周转率日数 (日) | 63.205日 | 60.807日 | 78.264日 | 94.624日 | 168.689日 |
| 应付贸易帐周转率日数 (日) | 42.650日 | 37.362日 | 42.486日 | 51.814日 | 41.079日 |
| 备注： | 实时报价更新时间为22/11/2024 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | HKD -47,969,000 |
| 增长率 | -42.861% |
| 每股盈利/(亏损) | HKD -0.017 |
| 每股账面资产净值 ($) | HKD -0.017 |